| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a5ff5cfcad6ae60a173d93a1856d7938 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-543
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55511 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7125
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0073
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7125
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713 |
| filingDate |
2016-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55216a181e7d24d9e8f1084f219d43f7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e25d18ebb4e9dfec21fd3d8d87be2c1 |
| publicationDate |
2018-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20180021700-A |
| titleOfInvention |
Intrapulmonary administration of polynucleotide Toll-like receptor 9 agonists to treat lung cancer |
| abstract |
This disclosure relates to a method of treating cancer by intrapulmonary administration of a polynucleotide Toll-like receptor 9 agonist. The method of the present disclosure is suitable for treating primary lung cancer, as well as metastatic cancer to the lung and its extra-lung cancer. In addition, the disclosure provides polynucleotide Toll-like receptor 9 agonists with an immunostimulatory and toxic profile suitable for intrapulmonary administration. |
| priorityDate |
2015-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |